BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Market Closed - Euronext Paris 12:30:00 2024-07-15 pm EDT | ||
| 30.49 EUR | +1.31% |
|
| Current month | +4.86% | ||
| 1 month | +9.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-15 | 30.49 | +1.31% |
| 24-07-12 | 30.1 | +2.44% |
| 24-07-11 | 29.38 | -3.13% |
| 24-07-10 | 30.34 | +3.02% |
| 24-07-09 | 29.45 | +1.26% |
Real-time Euronext Paris
Last update July 15, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| BE81S | |
| ISIN | DE000SH8J774 |
| Date issued | 2022-04-08 |
| Strike | 290.7 $ |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 2.91 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 31.12 € |
|---|---|
| Lowest since issue | 1.599 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
950.5
USD
Average target price
893.1
USD
Spread / Average Target
-6.04%
- Stock Market
- Certificates
- BE81S Certificat
